secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001404644-25-000053
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene shareholders approve equity plan amendments, elect directors
----------------------------------------------------------------------

- Amendments to 2023 Equity Incentive Plan and ESPP approved; shares from prefunded warrants and convertible preferred counted in automatic share reserve increase.
- Elected Sarah B. Noonberg and Robert 'Keith' Woods as Class II directors until 2028; each received >10.3M votes for.
- Say-on-pay advisory vote passed with 7.72M for (68.7% of votes cast excluding broker non-votes).
- Ratified Deloitte & Touche as independent auditor for FY2025; 99.9% of votes cast in favor.
- Quorum of 11.48M shares (80.5% of voting power) present at the June 12, 2025 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/0001404644-25-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/ngne-20250612.htm
  HTML page:      https://secwatch.observer/filing/0001404644-25-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer